17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

17β-HSD (17β-Hydroxysteroid Dehydrogenases) is a class of NADPH/NAD+ dependent oxidoreductases that primarily catalyze the reversible conversion between the 17β-hydroxyl and ketone groups of steroid hormones, playing a crucial role in the synthesis, activation, and inactivation of steroids. The 17β-HSD family mainly belongs to the short-chain dehydrogenase/reductase (SDR) family, with the exception of 17β-HSD5 (AKR1C3), which belongs to the aldo-keto reductase (AKR) family. To date, 14 different mammalian 17β-HSDs have been identified, of which 12 are expressed in human tissues, exhibiting diverse tissue distributions, subcellular localizations, and catalytic preferences (oxidation or reduction).
17β-HSD1 primarily catalyzes the conversion of estrone (E1) to estradiol (E2) and is associated with breast cancer, prostate cancer, and endometriosis. 17β-HSD2 catalyzes the oxidation of E2 to E1, while also regulating the interconversion between androstenedione (A4) and testosterone (T), playing a role in osteoporosis. 17β-HSD3 promotes the conversion of A4 to T and is crucial for male sexual differentiation. 17β-HSD4 is involved in fatty acid β-oxidation and steroid hormone inactivation. Additionally, 17β-HSD5 participates in steroid hormone and prostaglandin synthesis, whereas 17β-HSD7 is involved in cholesterol and estrogen biosynthesis. 17β-HSD10 exhibits broad substrate specificity, contributing to the metabolism of fatty acids, bile acids, and neurosteroids, and has been implicated in Alzheimer's disease (AD). The development of selective inhibitors targeting specific 17β-HSD isoforms has become an important strategy in related disease research^[1].

References:

[1]. Marchais-Oberwinkler S, et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol. 2011 May;125(1-2):66-82. [Content Brief]

17β-HSD Related Products (158):

By Effects:	Inhibitors (152) Activator (1) Modulators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-150649

S07-2005 (racemic)	Inhibitor
S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance.

HY-163253S

HSD17B13-IN-56-d₃	Inhibitor
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-157663

HSD17B13-IN-36	Inhibitor
HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).

HY-162212

HSD17B13-IN-85	Inhibitor
HSD17B13-IN-85 (186) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-183309

FXR/HSD17B13-modulator-2	Inhibitor
FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC₅₀ of 128 nM, human HSD17B13 IC₅₀ of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis.

HY-157613

HSD17B13-IN-5	Inhibitor
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).

HY-162211

HSD17B13-IN-84	Inhibitor
HSD17B13-IN-84 (182) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-157601

HSD17B13-IN-4	Inhibitor
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).

HY-162224

HSD17B13-IN-98	Inhibitor
HSD17B13-IN-98 (5) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC₅₀ value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease.

HY-163256

HSD17B13-IN-59	Inhibitor
HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-43322

7-Coumaryl triflate	Inhibitor	98.96%
7-Coumaryl triflate is a type 17β-HSD1 inhibitor of 17β-hydroxysteroid dehydrogenase. Its IC₅₀ is 360 nM and K_i is 173 nM. 7-Coumaryl triflate shows selectivity for 17β-HSD2 and has no detectable affinity for ERα or ERβ. 7-Coumaryl triflate can be used in related research on hormone-dependent breast cancer.

HY-157654

HSD17B13-IN-26	Inhibitor
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.

HY-180915

Dehydrofalcarinol
Dehydrofalcarinol is a polyacetylene compound found in Desmanthodium guatemalense with anticancer activity. Dehydrofalcarinol shows anticancer activity depending on 17β-hydroxysteroid dehydrogenase (17β-HSD) type 11. Dehydrofalcarinol can be used for the research of triple-negative breast cancer.

HY-103394R

TC HSD 21 (Standard)	Inhibitor
TC HSD 21 (Standard) is the analytical standard of TC HSD 21 (HY-103394). This product is intended for research and analytical applications. TC HSD 21 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) against related 17β-HSD isozymes, with an IC₅₀ of 14 nM in HeLa cells. TC HSD 21 can be used in the research of prostate cancer.

HY-169238

17β-HSD7-IN-1	Inhibitor
17β-HSD7-IN-1 (compound 4) is an inhibitor of 17β-HSD7, with inhibitory effect agasint the formation of Estradiol (IC₅₀=63 nM)..

HY-107379R

AKR1C3-IN-1 (Standard)	Inhibitor
AKR1C3-IN-1 (Standard) is the analytical standard of AKR1C3-IN-1 (HY-107379). This product is intended for research and analytical applications. AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC₅₀ of 13 nM.

HY-164136

17β-HSD5 inhibitor 1	Inhibitor
17β-HSD5 inhibitor 1 (Compound 29) is a potent 17β-HSD5 inhibitor, with an IC₅₀ of 2.9 nM in HEK-293 cells overexpressing human 17β-HSD5.

HY-164137

17β-HSD5 inhibitor 2	Inhibitor
17β-HSD5 inhibitor 2 (Compound 30) is an inhibitor for 17β-hydroxysteroid dehydrogenases 5 (17β-HSD 5) with IC₅₀ of 40 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.